肿瘤化疗辅助用药研究进展
r （r-metHuG-CSF）.N Engl J Med ,1991,325:164-170.
16. 冯奉仪，周立强.基因重组人粒细胞/巨噬细胞集落刺激因子防治肿瘤化疗所致的白细胞减少。中华肿瘤杂志1998，20（6）：451-453.
17. Maher D, Green M, Bishop J, et al. Randomized, placebo controlled trial of filgrastim （r-metHuG-CSF） in patients with febrile neutropenia （FN）following chemotherapy（CT）. Proc Am Soc Clin Oncol, 1993,12:434（abstr）.
18. Kemp G, Rose P, Lurain J ,et al. Amifostine pretreatment for protection against cyclophophamide-induced and cisplatin-induced toxicities: Results of a randomized
19. Hortobagyi GN, Theriault RL, Porter L,et al. Efficacy of pamidronate in reducing skeletal complications in patients with breasr cancer and lytic bone metastases. N Engl J Med, 1996,335:1785-1791.
20. Patterson AHG, Powel TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol,1993, 11: 59-65.
21. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol,1993,11:491-498.
22. Kanis JA, Powles T, Paterson AHG, et al. Clodronate decrease the frequency of skeletal metastases in women with breast cancer. Bone, 1996,19: 663-667.
23. Van Holten-verzantrvoort AT, Hermas J, Beex LV, et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patient? Eur J Cancer, 1996,32A:450-454.
24. Loyama, Uchida T, Takanuki F,et al. Pharmacokinetics of recombinant human interleukin-11（rhIL-11） in healthy male subjects. Br J Clin Pharmacol, 1997,43:571-578.
25. Tepler I, Elias L, Smith II JW,et al. A randomized placebo-controlled trial of recombinant human interliukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood, 1996,87（9）:3607-3614.&nbs
16. 冯奉仪，周立强.基因重组人粒细胞/巨噬细胞集落刺激因子防治肿瘤化疗所致的白细胞减少。中华肿瘤杂志1998，20（6）：451-453.
17. Maher D, Green M, Bishop J, et al. Randomized, placebo controlled trial of filgrastim （r-metHuG-CSF） in patients with febrile neutropenia （FN）following chemotherapy（CT）. Proc Am Soc Clin Oncol, 1993,12:434（abstr）.
18. Kemp G, Rose P, Lurain J ,et al. Amifostine pretreatment for protection against cyclophophamide-induced and cisplatin-induced toxicities: Results of a randomized
control trail in patients with advanced ovarian cancer. J Clin Oncol, 1996,14:2101-2112.
19. Hortobagyi GN, Theriault RL, Porter L,et al. Efficacy of pamidronate in reducing skeletal complications in patients with breasr cancer and lytic bone metastases. N Engl J Med, 1996,335:1785-1791.
20. Patterson AHG, Powel TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol,1993, 11: 59-65.
21. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol,1993,11:491-498.
22. Kanis JA, Powles T, Paterson AHG, et al. Clodronate decrease the frequency of skeletal metastases in women with breast cancer. Bone, 1996,19: 663-667.
23. Van Holten-verzantrvoort AT, Hermas J, Beex LV, et al. Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patient? Eur J Cancer, 1996,32A:450-454.
24. Loyama, Uchida T, Takanuki F,et al. Pharmacokinetics of recombinant human interleukin-11（rhIL-11） in healthy male subjects. Br J Clin Pharmacol, 1997,43:571-578.
25. Tepler I, Elias L, Smith II JW,et al. A randomized placebo-controlled trial of recombinant human interliukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood, 1996,87（9）:3607-3614.&nbs
- 上一篇论文：
- 下一篇论文：